Drug Trial Radar · NCT03458559
Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy
Last checked: Nov 20, 2026Latest source record: Nov 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
402
Planned (sponsor's estimate)
Start
May 16, 2018
Primary completion
May 16, 2022
Study completion May 16, 2024
Sponsor
- Lead sponsor
- Amsterdam UMC, location VUmcAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 8, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Radium-223 chloride is an alpha-emitting radiopharmaceutical with proven survival benefit in patients with castration-resistant prostate cancer metastatic to bone. Beta-emitting radiopharmaceuticals have proven efficacy for palliating malignant bone pain. Nowadays, rhenium-188-HEDP is used in clinical practice for pain relief and palliative care. Several studies suggest that also rhenium-188-HEDP has the potential to improve overall survival. The purpose of this study is to investigate if treatment with rhenium-188-HEDP results in improvement of overall survival compared to treatment with radium-223-chloride.
Conditions
- Prostate Cancer Metastatic to Bone
Interventions
Radium-223 chlorideDrug
Intravenously 50 kBq/kg every 4 weeks. Total: 6 administrations
Rhenium-188-HEDPDrug
Intravenously 40 MBq/kg every 8 weeks. Total: 3 administrations
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: Time from randomization until death due to any cause, an average of 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
VU University Medical Center
Amsterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.